Press & News

The next generation biopharmaceuticals

Press releases 2017

2017-12-01

Bästa aktieägare i Affibody Medical AB

Vid extra bolagsstämma i bolaget den 23 november i år beslöts att genomföra en nyemission av aktier i bolaget.[read more]

Older press releases

2017-11-17

Interim Report – January to September 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2017[read more]

2017-11-08

Kallelse till extra bolagsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma torsdagen den 23 november 2017 kl 16.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.[read more]

2017-09-06

Affibody Announces Presentation of Interim Data from Phase I/II Clinical Trial of ABY-035 at European Academy of Dermatology and Venereology

Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced that interim data from the ongoing Phase I/II study of ABY-035 will be presented at...[read more]

Affibodys latest Press releases

2021-06-02

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby given notice...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information